Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Partial characterization and "quantitation" of a human prostatic estramustine-binding protein

P Björk, B Forsgren, J A Gustafsson

    Cancer Research
    |May 1, 1982
    PubMed
    Summary

    Researchers partially characterized human estramustine-binding protein (HEMBP), finding it distinct from albumin. HEMBP was detected in benign and malignant prostate tissues, suggesting its potential role in estramustine phosphate therapy for prostate cancer.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    S-testosterone decrease after a mixed meal in healthy men independent of SHBG and gonadotrophin levels.

    Andrologia·2012
    Same author

    Ezrin mediates c-Myc actions in prostate cancer cell invasion.

    Oncogene·2009
    Same author

    Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.

    Gut·2006
    Same author

    Androgens induce CD-9 in human prostate tissue.

    International journal of andrology·2005
    Same author

    Tissue concentrations of tissue polypeptide antigen (TPA) and prostatic specific antigen (PSA) in 42 patients with prostatic carcinoma.

    The Prostate·2000
    Same author

    Estrogens increase the endothelial nitric oxide synthase (ecNOS) mRNA level in LNCaP human prostate carcinoma cells.

    The Prostate·2000

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Oncology

    Background:

    • Estramustine phosphate (Estracyt) is used to treat prostate cancer.
    • Understanding the estramustine-binding macromolecule in prostate tissue is crucial for optimizing therapy.

    Purpose of the Study:

    • To partially characterize the [3H]estramustine-binding macromolecule in human prostate, termed human estramustine-binding protein (HEMBP).
    • To determine if HEMBP is distinct from human serum albumin.
    • To investigate the presence and concentration of HEMBP in benign hyperplastic prostate, cancerous prostate, and normal prostate tissues.

    Main Methods:

    • Gel filtration (Sephacryl S-200 Superfine) and high-performance liquid chromatography for molecular weight determination.
    • Sucrose density gradient centrifugation for sedimentation coefficient.

    Related Experiment Videos

  • Isoelectric focusing and chromatofocusing for isoelectric point.
  • Affinity chromatography (concanavalin A-Sepharose, diethylaminoethyl-Sepharose) to assess properties and purity.
  • Radioimmunoassay (EMBP) to quantify HEMBP in tissue samples.

    • Main Results:

    • HEMBP has an estimated molecular weight of 54,000 and a sedimentation coefficient of 3.6S.
    • HEMBP is a glycoprotein with an isoelectric point of 4.7-4.8.
    • HEMBP was successfully separated from human serum albumin using various chromatographic techniques.
    • HEMBP was detected in 22 of 27 benign hyperplastic prostate samples, 4 of 7 cancer specimens, and 2 of 2 normal prostate specimens.

    Conclusions:

    • Human estramustine-binding protein (HEMBP) has been partially characterized and shown to be distinct from human serum albumin.
    • The presence of HEMBP in benign, cancerous, and normal prostate tissues indicates its potential relevance in estramustine phosphate therapy.
    • HEMBP concentration in malignant tissue may influence drug uptake and treatment efficacy for prostate carcinoma.